| Спонсоры |
Ведущий спонсор: Zymeworks Inc. Коллаборационист: BeiGene, Ltd. |
|---|---|
| Источник | Zymeworks Inc. |
| Краткое содержание | This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic). |
| Общий статус | Recruiting | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Дата начала | 2021-12-02 | ||||||||||||||||||||||||||
| Дата завершения | 2025-07-01 | ||||||||||||||||||||||||||
| Дата первичного завершения | 2024-06-01 | ||||||||||||||||||||||||||
| Фаза | Phase 3 | ||||||||||||||||||||||||||
| Тип исследования | Interventional | ||||||||||||||||||||||||||
| Первичный результат |
|
||||||||||||||||||||||||||
| Вторичный результат |
|
||||||||||||||||||||||||||
| Регистрация | 714 |
| Состояние |
|
|---|---|
| Вмешательство |
Тип вмешательства: Drug Название вмешательства: Zanidatamab Описание: Administered IV Другое имя: ZW25 Тип вмешательства: Drug Название вмешательства: Tislelizumab Описание: Administered IV Этикетка Arm Group: Arm C Тип вмешательства: Drug Название вмешательства: Trastuzumab Описание: Administered intravenously (IV) Этикетка Arm Group: Arm A Другое имя: Herceptin® Тип вмешательства: Drug Название вмешательства: Capecitabine Описание: Administered orally (PO bid) Тип вмешательства: Drug Название вмешательства: Oxaliplatin Описание: Administered IV Тип вмешательства: Drug Название вмешательства: Cisplatin Описание: Administered IV Тип вмешательства: Drug Название вмешательства: Описание: Administered IV Тип вмешательства: Diagnostic Test Название вмешательства: In situ hybridization (ISH)-based companion diagnostic assay Описание: Subjects will be tested for HER2 gene-amplification using the ISH-based companion diagnostic assay Тип вмешательства: Diagnostic Test Название вмешательства: Immunohistochemistry (IHC)-based companion diagnostic assay Описание: Subjects will be tested for HER2 protein-expression using the IHC-based companion diagnostic assay |
| Приемлемость |
Критерии: Inclusion Criteria: - Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment - Assessable (measurable or non-measurable) disease as defined by RECIST 1.1 - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization - Adequate organ function - Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA) Exclusion Criteria: - Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA - Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways - Prior treatment with systemic antineoplastic therapy for unresectable locally advanced, recurrent or metastatic GEA - Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization) - Known history of or ongoing leptomeningeal disease (LMD) - Known additional malignancy that is not considered cured or that has required treatment within the past 3 years - Known active hepatitis - Any history of human immunodeficiency virus (HIV) infection - Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible - QTc Fridericia (QTcF) > 470 ms - Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF) Пол: All Минимальный возраст: 18 Years Максимальный возраст: N/A Здоровые волонтеры: No |
| Общий Официальный |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общий контакт |
Фамилия: Zymeworks Clinical Trial Resource Телефон: 206-237-1030 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Расположение |
|
| Расположение Страны |
Chile China Greece Korea, Republic of Romania Spain Ukraine |
|---|---|
| Дата проверки |
2022-02-01 |
| Ответственная сторона |
Тип: Sponsor |
| Ключевые слова |
|
| Имеет расширенный доступ | Yes |
| Состояние Просмотр |
|
| Количество рук | 3 |
| Группа вооружений |
Метка: Arm A Тип: Active Comparator Описание: Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) Метка: Arm B Тип: Experimental Описание: Zanidatamab plus physician's choice of CAPOX or FP Метка: Arm C Тип: Experimental Описание: Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP |
| Акроним | HERIZON-GEA-01 |
| Данные пациента | No |
| Информация о дизайне исследования |
Распределение: Randomized Модель вмешательства: Parallel Assignment Описание модели вмешательства: multi-cohort, open-label, multicenter study Первичное назначение: Treatment Маскировка: None (Open Label) |